Related Experiment Video
Updated: Jan 10, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
7.3K
Therapeutic Plasma Exchange Resolves Inflammation With Increased HSD11B1 in Kawasaki Disease
Shuji Sai1,2, Soichiro Wada1, Shigetoshi Ogiwara1
1Department of Pediatrics, Teine-Keijinkai Hospital, Sapporo, Japan.
Journal of Clinical Apheresis
|November 21, 2025
Summary
Therapeutic plasma exchange (TPE) is effective for treating refractory Kawasaki disease (KD). This study explores TPE
Area of Science:
- Pediatric rheumatology
- Immunology
- Cardiology
Background:
- Kawasaki disease (KD) is a critical pediatric inflammatory condition.
- Coronary artery aneurysms are a severe complication in treatment-resistant KD.
- Therapeutic plasma exchange (TPE) shows promise for refractory cases.
Purpose of the Study:
- To evaluate the effectiveness of TPE in refractory Kawasaki disease.
- To investigate the role of 11beta-hydroxysteroid dehydrogenase 1 in KD inflammation resolution.
Main Methods:
- Investigated the clinical effectiveness of TPE in refractory KD patients.
- Assessed the involvement of 11beta-hydroxysteroid dehydrogenase 1 in inflammation resolution.
Main Results:
- TPE demonstrated effectiveness in managing refractory KD.
- The study elucidated the role of 11beta-hydroxysteroid dehydrogenase 1 in the inflammatory process.
Conclusions:
- TPE is a viable treatment option for refractory Kawasaki disease.
- Understanding the 11beta-hydroxysteroid dehydrogenase 1 pathway may offer new therapeutic targets.
More Related Videos
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
460
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
460
01:28Inflammatory Response
15.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.9K
01:21Rheumatic Heart Disease III: Medical Management
268
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
268
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465